Vincrist® (Vincristine Sulfate USP), is the salt of an alkaloid obtained from a common flowering herb, the periwinkle plant (Vinca rosea Linn). Originally known as leurocristine, it has also been referred to as LCR and VCR. Vincrist is a white to off-white powder and is
soluble in methanol, freely soluble in water, but only slightly soluble in ethanol. The molecular formula of Vincrist is C46H56N4O10•H2SO4. It has a molecular weight of 923.04 and its structural formula is as follows:
Each box contains one vial of Vincristine Sulfate USP 1mglyophilized powder and a ampoule of supplying solvent. Each box contains one vial of Vincristine Sulfate USP 2mg lyophilized powder and a vial of supplying solvent.
Mechanism of action
Tubulin is a structural protein which polymerizes to action microtubules. Vincristine binds to tubulin dimers & inhibits the formation of microtubule in mitotic spindle. Resulting in an arrest mitosis at the metaphase stage.
Protein binding 75%
Half-life 19-155 hours
Excretion Mostly biliary, 10% in urine
Vincrist® is indicated in acute leukemia, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor. It is also used in combination with other oncolytic agents in Hodgkin’s disease, non–Hodgkin’s malignant lymphomas.
Dosage and administration
Usual dosage and schedule 1 to 2 mg/m2 (maximum 2.0 to 2.4 mg) I.V. weekly. 0.4 mg/day as a continuous I.V. infusion on days 1 to 4.
Possible side effects
Gastrointestinal – Constipation, nausea, vomiting.
Genitourinary – Polyuria, dysuria & urinary retention (bladder atony.)
Cardiovascular – Hypertension and hypotension.
Neurologic – Frequently, there is a sequence to the development of neuromuscular side effects.
Patients with the demyelinating form of Charcot–Marie–Tooth (syndrome of arms and foot) should not be given Vincrist.
Vincristine sulfate should not be diluted in solutions that raise or lower the pH outside the range of 3.5 – 5.5. It should not be mixed with anything other than normal saline or glucose in water.
Administer as a slow I.V., taking care to avoid extravasations, because neurotoxicity is cumulative, neurologic evaluation should be done before each dose and therapy withheld if severe paresthesias, motor weakness or other severe abnormalities occur. If liver disease is significant, dose should be reduced. Stool softeners or high-fiber or bulk diets may avert severe constipation.
Vincrist® 1 mg & 2 mg for I.V. injection should be reconstituted with the supplied solvent to obtain approximately isotonic solution under the supervision of registered oncologist.
The further diluted solution must be used within 6 hours if stored at room temperature or 24 hours if refrigerated.
Product should be refrigerated between 2°C–8°C and protected from light. Unused solution should be discarded.
Vincrist® 2 mg inj.: Each box contains 1 vial of Vincristine Sulfate USP 2 mg and one vial of solvent.